Regeneron Pharmaceuticals, Inc. (REGN)
REGNNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$955.47
-1.16 (-0.12%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $98.84bn
- P/E
- 20.0
- EPS, last 4 quarters
- $47.76
- Dividend yield
- 0.40%
- Day range
- –
- 52-week range
- $591.52 to $991.73
- Average volume
- –
- Previous close
- $956.63
Analysts
24 coveringBuy16 buy, 8 hold, 0 sell
Targets a year out average $958.17, +0.3% from here
Earnings
next estimate $21.28Next report
Dec 2025
+12.3%
Mar 2026
+19.4%
Jun 2026
+56.6%
Sep 2026
+33.9%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $3.88bn | $3.61bn | $4.29bn | $5.12bn |
| Gross profit | $3.30bn | $2.94bn | $3.71bn | $4.54bn |
| Operating income | $879.90m | $642.90m | $1.29bn | $2.05bn |
| Net income | $844.60m | $727.20m | $1.30bn | $1.95bn |
Last four quarters: revenue $16.90bn, margin 28.5%, free cash flow $3.83bn
News
8 latest- Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?The Motley Fool · 23 hours ago
- Kodiak Q3 Loss Wider Than Expected, Pipeline Development in FocusZacks · 1 day ago
- REGN Soars 27.4% in a Month: Buy, Sell or Hold the Stock? Zacks · 3 days ago
- Why Regeneron (REGN) is a Top Value Stock for the Long-TermZacks · 4 days ago
- Bayer Wins FDA Approval for Sunharbo for Secondary Stroke Risk ReductionZacks · 5 days ago
- Regeneron Pharmaceuticals Advances Liver Drug After Early Trial Cuts Liver Fat by Up to 80%MarketBeat · 5 days ago
- Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run?Zacks · 5 days ago
- Noteworthy ETF Inflows: JEPQ, REGN, SNPS, MNSTBNK Invest · 6 days ago
The company
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite , which produces optimized fully human antibodies and new classes of bispecific antibodies.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- regeneron.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.